Splenic artery infusion of IL-2 might allow treatment of melanoma and renal cell cancer with less side effects and greater efficacy

<p>Treatment of stave IV renal cell cancer and melanoma with intravenous interleukin-2 (IL-2) is often limited by side effects, and only a minority of patients obtain sustained remissions. This editorial proposes that infusing IL-2 into the splenic artery will allow much stronger immune activa...

Full description

Bibliographic Details
Main Author: Joseph Martin Alisky
Format: Article
Language:English
Published: IJCTO 2014-02-01
Series:International Journal of Cancer Therapy and Oncology
Subjects:
Online Access:http://ijcto.org/index.php/IJCTO/article/view/80